# US 2021/0332131 A1 · COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332131 A1
- Document ID: US20210332131A1
- Status: Published application
- Kind: A1
- Application number: 17/242,793
- Filed: 2021-04-28
- Published: 2021-10-28
- Earliest claimed: 2018-10-30
- Assignees: TigaTX, Inc.; UMC Utrecht Holding B.V.
- Applicants: TigaTX, Inc.; UMC Utrecht Holding B.V.
- Inventors: Mark De Boer; Jeannette Henrica Wilhelmina LEUSEN; Geert Jan VAN TETERING
- Web page: https://patentgrep.com/patent/US20210332131A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 35/00: Antineoplastic agents
- C07K 16/2887: {against CD20}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are therapeutic agents, pharmaceutical compositions, and methods comprising an IgA constant region. The compositions and methods described herein facilitate binding of an antibody construct comprising an IgA constant domain to CD47 and an antigen for instance a tumor related antigen such as CD20 or CD19.

## Claims

### Claim 1

An antibody construct comprising;
(a) an immunoglobulin A (IgA) heavy chain domain;
(b) a CD47 binding domain; and
(c) an antigen binding domain;
wherein the IgA heavy chain domain specifically binds a FcαR on an immune effector cell,
wherein the CD47 binding domain inhibits binding of a CD47 expressed on a target cell with a signal regulatory protein α (SIRP α) on the immune effector cell,
wherein the antigen binding domain binds an antigen on the target cell, and
wherein the antibody construct has a higher binding affinity for the antigen compared to the CD47.
